Sign in Register

Zithromax (azithromycin)

Advertisement

Last reviewed · Source: First Databank (FDB) drug data

Overview

Azithromycin is an azalide antibiotic, a subclass of macrolide antibiotics.

Pending revision, the material in this section should be considered in light of more recently available information in the MedWatch notification at the beginning of this monograph.

Generic name: azithromycin
Pronunciation: (ay-ZITH-roe-MYE-sin)

Reference product & biosimilars

No reference, biosimilar or interchangeable associated with this drug.

Today’s intelligence on Zithromax

Intelligence content is not available yet.

Indications

The following indications are listed for Zithromax:

  • Bacterial Pneumonia
  • Chlamydia Trachomatis Pelvic Inflammatory Disease
  • Chlamydial Pneumonia
  • Haemophilus Influenzae Pneumonia
  • Legionella Pneumophila Pneumonia
  • Moraxella Catarrhalis Pneumonia
  • Mycoplasma Hominis Pelvic Inflammatory Disease
  • Mycoplasmal Pneumonia
  • Pelvic Inflammatory Disease With Neisseria Gonorrhea
  • Pneumococcal Pneumonia
  • Pneumonia Due To Staphylococcus Aureus

Also known as: Eaton Agent Pneumonia, H. Flu Pneumonia, H. Influenzae Pneumonia, Hemophilus Influenzae Pneumonia, Infection Of The Lungs Due To Chlamydia, Influenza Bacillus Pneumonia, Pelvic Inflammatory Disease Due To Chlamydia Trachomatis, Pelvic Inflammatory Disease Due To Mycoplasma Hominis, Pelvic Inflammatory Disease Due To Neisseria Gonorrhea, Pfeiffer's Bacillus Pneumonia, Pid Due To Chlamydia Trachomatis, Pid Due To Mycoplasma Hominis, Pneumonia Due To B. Catarrhalis, Pneumonia Due To Branhamella Catarrhalis, Pneumonia Due To Haemophilus Influenzae, Pneumonia Due To M. Catarrhalis, Pneumonia Due To Moraxella Catarrhalis, Pneumonia Due To Neisseria Catarrhalis, Pneumonia Due To Staphylococcus Pyogenes Aureus, Pneumonia Due To Streptococcus Pneumoniae, Primary Atypical Pneumonia.

Dosing

Pending revision, the material in this section should be considered in light of more recently available information in the MedWatch notification at the beginning of this monograph.

Dosage of azithromycin, which is commercially available for oral and IV use as the dihydrate, is expressed in terms of anhydrous azithromycin.

Two 250-mg tablets of azithromycin are bioequivalent to one 500-mg tablet. The extended-release oral suspension is not bioequivalent to and is not interchangeable with the conventional oral suspension or tablets.

Dosage adjustment is not necessary in patients with renal impairment (glomerular filtration rate 80 mL/minute or less). However, data are limited regarding use of azithromycin in patients with severe renal impairment (glomerular filtration rate less than 10 mL/minute) and the manufacturer states that the drug should be used with caution in these patients.

The pharmacokinetics of azithromycin in patients with hepatic impairment have not been established. The manufacturer states that data are insufficient to make dosage recommendations for patients with hepatic impairment and azithromycin should be used with caution in such patients since the drug is eliminated principally via the liver. Based on results of a limited study in patients with impaired hepatic function, some clinicians state that dosage adjustments are not necessary in patients with class A or B liver cirrhosis.

Drug interactions

There is no enhanced messaging for this drug.

Contraindications

There is no enhanced messaging for this drug.

Adverse reactions

There is no enhanced messaging for this drug.

Precautions

No enhanced messaging available.

ICD codes

No ICD codes are available for this drug.

Formulary status

Search health-plan coverage for this drug by ZIP code.

Enter a 5-digit ZIP code. Searching does not change your profile.

Enter a ZIP code to view available health plans.

Last reviewed · Source: First Databank (FDB) drug data